ImageAstraZeneca-Headquarters.jpg” style=”padding: 10px” width=”277″ />

AstraZeneca has signed an exclusive global licence agreement for rights to Synairgen’s SNG001, an inhaled interferon beta in clinical development for treating respiratory tract viral infections in patients with severe asthma.

Under the terms of the licence agreement, Synairgen will receive $7.25m up-front fee and potential development, and will receive regulatory and commercial milestones of up to $225m from AstraZeneca.

Synairgen will also receive tiered royalties from AstraZeneca ranging from single-digit up to mid-teens on commercial sales. AstraZeneca will be responsible for future development costs.

AstraZeneca will initiate a Phase IIa study in early 2015 in severe asthma patients, building on available clinical data from an initial Phase lla trial in a broad asthma population.

"AstraZeneca will initiate a Phase IIa study in early 2015 in severe asthma patients."

SNG001 also provides the opportunity to expand the clinical programme in other pulmonary diseases including chronic obstructive pulmonary disease.

Synairgen CEO Richard Marsden said: "With its strong research focus and extensive experience in respiratory disease, AstraZeneca’s commitment to developing novel medicines for patients with asthma and COPD makes them the ideal partner for SNG001."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

SNG001 has a broad spectrum anti-viral effect and contains interferon-beta that occurs naturally in the body. The drug supports the immune system by correcting a deficiency that makes patients vulnerable to respiratory tract viral infections.

It delivers interferon-beta to the lungs when an infection begins to develop in the upper airways. Inhaled interferon-beta boosts the anti-viral defence and combats the spread of the virus, preventing or reducing the severity of exacerbations.

Image: AstraZeneca headquarters in London, UK. Photo: courtesy of AstraZeneca plc.